Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

被引：1

作者：

Carter, Bing Z.

Mak, Po Yee

Ruvolo, Vivian

Tao, Wenjing

Hughes, Paul

Chen, Xiaoyue

Morrow, P. K.

Andreeff, Michael

机构：

来源：

BLOOD | 2020年 / 136卷

关键词：

D O I：

10.1182/blood-2020-141399

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor [J].

Tse, KF ;

Allebach, J ;

Levis, M ;

Smith, BD ;

Bohmer, FD ;

Small, D .

LEUKEMIA, 2002, 16 (10) :2027-2036

[22] Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor [J].

James, Angela Joubert ;

Smith, Catherine C. ;

Litzow, Mark ;

Perl, Alexander E. ;

Altman, Jessica K. ;

Shepard, Dale ;

Kadokura, Takeshi ;

Souda, Kinya ;

Patton, Melanie ;

Lu, Zheng ;

Liu, Chaofeng ;

Moy, Selina ;

Levis, Mark J. ;

Bahceci, Erkut .

CLINICAL PHARMACOKINETICS, 2020, 59 (10) :1273-1290

[23] Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor [J].

Angela Joubert James ;

Catherine C. Smith ;

Mark Litzow ;

Alexander E. Perl ;

Jessica K. Altman ;

Dale Shepard ;

Takeshi Kadokura ;

Kinya Souda ;

Melanie Patton ;

Zheng Lu ;

Chaofeng Liu ;

Selina Moy ;

Mark J. Levis ;

Erkut Bahceci .

Clinical Pharmacokinetics, 2020, 59 :1273-1290

[24] Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML [J].

Yilmaz, Musa ;

Kantarjian, Hagop ;

Short, Nicholas J. ;

Reville, Patrick ;

Konopleva, Marina ;

Kadia, Tapan ;

DiNardo, Courtney ;

Borthakur, Gautam ;

Pemmaraju, Naveen ;

Maiti, Abhishek ;

Jabbour, Elias ;

Jain, Nitin ;

Issa, Ghayas ;

Takahashi, Koichi ;

Sasaki, Koji ;

Ohanian, Maro ;

Pierce, Sherry ;

Tang, Guillin ;

Loghavi, Sanam ;

Patel, Keyur ;

Wang, Sa A. ;

Garcia-Manero, Guillermo ;

Andreeff, Michael ;

Ravandi, Farhad ;

Daver, Naval .

BLOOD CANCER JOURNAL, 2022, 12 (05)

[25] Go6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1 [J].

Yoshida, Akira ;

Ookura, Miyuki ;

Zokumasu, Kouichi ;

Ueda, Takanori .

BIOCHEMICAL PHARMACOLOGY, 2014, 90 (01) :16-24

[26] Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML [J].

Musa Yilmaz ;

Hagop Kantarjian ;

Nicholas J. Short ;

Patrick Reville ;

Marina Konopleva ;

Tapan Kadia ;

Courtney DiNardo ;

Gautam Borthakur ;

Naveen Pemmaraju ;

Abhishek Maiti ;

Elias Jabbour ;

Nitin Jain ;

Ghayas Issa ;

Koichi Takahashi ;

Koji Sasaki ;

Maro Ohanian ;

Sherry Pierce ;

Guillin Tang ;

Sanam Loghavi ;

Keyur Patel ;

Sa A. Wang ;

Guillermo Garcia-Manero ;

Michael Andreeff ;

Farhad Ravandi ;

Naval Daver .

Blood Cancer Journal, 12

[27] FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 [J].

Goemans, Bianca F. ;

Zwaan, Christian M. ;

Cloos, Jacqueline ;

de Lange, Desiree ;

Loonen, Anne H. ;

Reinhardt, Dirk ;

Hahlen, Karel ;

Gibson, Brenda E. S. ;

Creutzig, Ursula ;

Kaspers, Gertjan J. L. .

LEUKEMIA RESEARCH, 2010, 34 (10) :1302-1307

[28] Coadministration of AZD 4573 and gilteritinib exhibits a potent activity in FLT3 inhibitor-sensitive and -resistant AML cells [J].

Rahmani, Mohamed ;

Salah, Baraa Khalid ;

Yener, Burcu ;

Mahboub, Bassam ;

Grant, Steven .

MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

[29] Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3-ITD Mutated Acute Myeloid Leukemia (AML) [J].

Skwarska, Anna ;

Panis, Paul ;

Zhang, Qi ;

Herbrich, Shelley ;

Kurvilla, Vinitha M. ;

Baran, Natalia ;

Halilovic, Ensar ;

Ruvolo, Peter ;

Ruvolo, Vivian ;

Morris, Erick ;

Wei, Andrew ;

Moujalled, Donia ;

Derreal, Alix ;

Banquet, Sebastien ;

Andreeff, Michael ;

Konopleva, Marina .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S220-S221

[30] Concurrent treatment with Pim kinase inhibitor enhances efficacy of FLT3 inhibitors in AML with FLT3-ITD through GSK-3βactivation and GSK-3β-mediated enhanced proteasomal degradation of c-Myc and Mcl-1 [J].

Lee, Jonelle ;

Scarpa, Mario ;

Chatterjee, Aditi ;

Ali, Mooath Mustafa ;

Singh, Prerna ;

Kapoor, Shivani ;

Trotta, Rossana ;

Baer, Maria .

CANCER RESEARCH, 2022, 82 (12)

← 1 2 3 4 5 →